Effective Dosing of Topotecan With Carboplatin in Relapsed Ovarian Cancer: A Phase I/II Study

作者
A. Bowman,Tzyvia Rye,G. Ross,Antony M. Wheatley,J F Smyth
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:19 (13): 3255-3259 被引量:18
标识
DOI:10.1200/jco.2001.19.13.3255
摘要

PURPOSE: This phase I/II study was performed to evaluate the feasibility of administering the topoisomerase inhibitor topotecan in combination with carboplatin. PATIENTS AND METHODS: Topotecan was given as a 30-minute infusion daily for 5 days, with carboplatin given immediately after topotecan on day 5. Treatment was repeated every 21 days. Carboplatin and then topotecan were escalated in sequential cohorts of three to six patients. Four dosage combinations of topotecan days 1 to 5 and carboplatin (day 5) were tested: 0.5 mg/m(2)/d and carboplatin area under the curve (AUC) of 4, topotecan 0.5 mg/m(2)/d and carboplatin AUC of 5, topotecan 0.75 mg/m(2)/d and carboplatin AUC of 5, and topotecan 1.0 mg/m(2)/d and carboplatin AUC of 5. RESULTS: Grade 3 and 4 neutropenia was common at doses of 0.75 mg/m(2)/d and above, but dose-limiting hematologic toxicity occurred in only one patient. The most common reason for dose reduction or delay was failure of myelosuppression to resolve by day 21. Nonhematologic toxicity was generally mild. The maximum-tolerated dose as defined in the protocol was not reached, but topotecan dose escalation was stopped at 1.0 mg/m(2)/d, because delayed neutrophil recovery precluded re-treatment on a 21-day schedule. CONCLUSION: Hematologic toxicity was common but rarely serious, and the combination of topotecan with carboplatin on this schedule was safe and well tolerated. Giving carboplatin to patients after topotecan on day 5, rather than on day 1, allowed dose escalation beyond the levels reported in other studies. The recommended doses for previously treated patients are topotecan 0.75 mg/m(2)/d, days 1 to 5, with carboplatin at an area under the curve (AUC) of 5 following topotecan on day 5. The combination of topotecan 1 mg/m(2)/d, days 1 to 5, followed on day 5 by carboplatin at an AUC of 5, merits further examination in untreated patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZMJJKK完成签到,获得积分20
刚刚
机智雅山发布了新的文献求助10
1秒前
2秒前
开放的书文完成签到,获得积分10
2秒前
听听完成签到,获得积分10
2秒前
圈圈完成签到,获得积分10
2秒前
冷艳的冰旋完成签到,获得积分10
3秒前
桃哈多完成签到,获得积分10
4秒前
缓慢如曼完成签到 ,获得积分10
4秒前
无花果的应助被Wuliu采纳,获得10
5秒前
忧伤的小天鹅完成签到,获得积分20
6秒前
6秒前
7秒前
dakjdia完成签到,获得积分10
7秒前
Leavome完成签到,获得积分10
7秒前
8秒前
周xj发布了新的文献求助10
8秒前
9秒前
9秒前
9秒前
9秒前
风中的子默完成签到,获得积分10
10秒前
10秒前
10秒前
颜倾完成签到,获得积分10
11秒前
在水一方的应助被豆豆采纳,获得10
12秒前
12秒前
dzxlgw完成签到,获得积分10
13秒前
小小完成签到,获得积分20
13秒前
13秒前
yuuuuu发布了新的文献求助10
13秒前
保护好小鞠完成签到,获得积分20
13秒前
颜倾发布了新的文献求助10
14秒前
14秒前
Hello的应助被lily采纳,获得10
14秒前
wanci的应助被明理夏槐采纳,获得10
14秒前
zz完成签到,获得积分20
14秒前
junzzz完成签到 ,获得积分10
15秒前
Tia完成签到,获得积分10
15秒前
莫北发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183241
求助须知:如何正确求助?哪些是违规求助? 9572493
关于积分的说明 21826218
捐赠科研通 7780115
什么是DOI,文献DOI怎么找? 3433982
关于科研通互助平台的介绍 2558103
邀请新用户注册赠送积分活动 2480192